GET DAILY SIGNALSWest Pharmaceutical Services (WST) Delivers Strong Q3 Results with +36% EPS Growth
Key Takeaways
- Third-quarter revenue rose 8.7% year over year to $874.5 million, with organic (currency-adjusted) growth of 11.9%.
- Adjusted earnings per share (EPS) climbed 36% to $2.66, roughly 21% above Wall Street's consensus estimate of $2.20.
- Reported (GAAP, or Generally Accepted Accounting Principles) net income reached $214.0 million, or $3.02 per diluted share.
- High-Value Product (HVP) Components again led the way, growing about 20% organically and representing 53% of total company sales.
- Management raised its full-year 2026 outlook for revenue and adjusted EPS, citing strong execution.
Why These Results Matter
West Pharmaceutical Services supplies containment and delivery systems for injectable medicines to biopharmaceutical companies around the world. Its quarterly performance offers a useful window into demand trends in the injectables space, including biologics and high-growth areas such as GLP-1 treatments for diabetes and obesity. The third quarter of 2026 followed several periods of rising High-Value Product sales, so the focus was on whether that pace could hold as the contract-manufacturing side of the business navigated planned transitions. The company had also completed the divestiture of its SmartDose 3.5mL platform, giving a clearer picture of underlying operations.
Breaking Down the Reported Numbers
West reported third-quarter net sales of $874.5 million, an 8.7% increase from $804.6 million a year earlier, with organic growth of 11.9%. That topped Wall Street’s consensus estimate of about $827 million. Adjusted diluted EPS reached $2.66, up 36% from $1.96 in the prior-year quarter and $0.47 above the midpoint of the company’s own guidance. On a GAAP basis, net income rose to $214.0 million, or $3.02 per diluted share, from $140.0 million, or $1.92 per share.
The Proprietary Products segment posted $728.8 million in revenue, up 16.6% organically, driven by HVP Components that grew 20.3% organically to $466.7 million. HVP Delivery Devices advanced 26.4% organically, while Standard Products rose 3.1%. The West Vantage segment fell 6.6% organically to $145.7 million due to the expected wind-down of a continuous glucose monitoring program, though results still edged ahead of expectations. Gross margin expanded 310 basis points to 39.7%, and adjusted operating margin widened 420 basis points to 25.3%.
Management raised its full-year 2026 revenue guidance to a range of $3.41 billion to $3.42 billion and its adjusted EPS outlook to $9.38 to $9.48.
Market Reaction and Sentiment
Shares moved higher in early trading after the release. The combination of a sizable earnings beat, revenue above consensus, and a second straight upward revision to full-year guidance supported confidence in the company’s position in high-value injectable categories. Strength in HVP Components, now more than half of total sales, along with better-than-expected margin expansion, added to the positive tone. The West Vantage decline was largely anticipated because of the CGM program transition, which limited any negative reaction.
Forward Outlook and Areas to Watch
Looking ahead, the key question is whether momentum in HVP Components can continue. Management has highlighted regulatory-driven upgrades, biologics growth, and ongoing GLP-1 demand as longer-term supports, and the company added a notable number of HVP upgrade projects this year. Still, tougher year-over-year comparisons in the GLP-1 category could make growth rates harder to sustain at recent levels. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The SmartDose 3.5mL platform divestiture will create a modeling consideration for 2027, as its removal from organic growth calculations is expected to weigh on reported growth next year. Within West Vantage, the shift toward higher-value drug-handling programs should keep near-term segment growth muted as legacy programs roll off.
On the cost side, management noted continued capacity investments to expand HVP finishing operations in Europe and the United States, while indicating that capital expenditures should stay within the targeted range. Margin trajectory, pricing contribution, and free cash flow recovery will remain important to monitor as the company works through elevated inventory and receivables levels.
Using Tickeron Tools for Research
When analyzing results like these, I often turn to Tickeron’s AI Screener to quickly filter peers and spot patterns across the sector. It helps surface relevant comparables and technical signals that complement the fundamental read, supporting a more efficient review process without replacing traditional analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WST in +4.61% Uptrend, rising for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where WST advanced for three days, in 202 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on WST as a result. In 61 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for WST just turned positive on October 15, 2026. Looking at past instances where WST's MACD turned positive, the stock continued to rise in 31 of 52 cases over the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 156 of 230 cases where WST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
WST broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. WST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.807) is normal, around the industry mean (5.000). P/E Ratio (52.944) is within average values for comparable stocks, (37.535). Projected Growth (PEG Ratio) (2.925) is also within normal values, averaging (4.143). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (7.862) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceuticals, biologics, vaccines and consumer healthcare products
Industry PharmaceuticalsOther
Advertisement